Treatment strategy for relapsed/refractory mantle cell lymphoma was written by Ishizawa, Kenichi. And the article was included in Ketsueki Naika in 2021.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:
A review. According to Japanese data, the median age of onset is around 60 years, and the male-female ratio is 2:1 or higher, which is more common among males. This paper discusses treatment strategy for relapsed/refractory mantle cell lymphoma. Mantle cell lymphoma, its treatment options such as immunochemotherapy, mol.-targeted drug, and cell therapy were discussed. Also, discusses medical treatment effect after the first recurrence in young people, Treatment policy and future prospects. Currently, the combination therapy of various mol.-targeted drugs is being investigated, but the development is progressing with the ibrutinib and venetoclax combination therapy. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem